Want to see IPSC full AI Analyst Report?
IPSC Stock Chart & Stats
$2.14
-$0.02(-0.95%)
At close: 4:00 PM EDT
$2.14
-$0.02(-0.95%)
Day’s Range― - ―
52-Week Range$0.44 - $3.04
Previous Close$2.08
Volume496.67K
Average Volume (3M)528.52K
Market Cap
$378.45M
Enterprise Value$423.11
Total Cash (Recent Filing)$119.71M
Total Debt (Recent Filing)$34.63M
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Nov 05, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding181,075,320
10 Day Avg. Volume417,670
30 Day Avg. Volume528,522
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.54
Price to Sales (P/S)0.79
P/FCF Ratio-0.82
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.90Price Target Upside175.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.5
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash Runway And Balance Sheet FlexibilityThe reported cash position and extended runway give Century time to advance multiple clinical programs without immediate financing pressure. This supports sustained R&D execution, although it does not eliminate the need for eventual funding.
Regulatory Progress Across The PipelineRegulatory alignment reduces uncertainty around CNTY-813’s development path and supports the targeted Q4 2026 IND filing. Progress toward clinical testing can improve the platform’s partnering potential and establish value beyond preclinical research.
Scalable Allogeneic Manufacturing CapabilityConsistent clinical-scale manufacturing is important for an off-the-shelf cell therapy model because it can support reproducible quality and future commercial scalability. This strengthens execution prospects if CNTY-813 demonstrates clinical efficacy and safety.
Bears Say
No Current Recurring Product RevenueCentury remains a development-stage biotechnology company without current product revenue, leaving its economic model dependent on clinical success, approvals, and potential partnerships. This makes future cash generation highly uncertain over the next several years.
Persistent Losses And Operating Cash BurnLarge recurring losses and negative operating cash flow show that Century cannot currently self-fund development. Continued investment is necessary to advance the pipeline, but prolonged burn could require financing before products generate meaningful commercial cash flow.
Potential Shareholder Dilution From Authorized SharesThe larger authorized share pool gives Century flexibility to raise capital or pursue strategic actions, but future issuance could dilute existing holders. Given ongoing cash consumption and no product revenue, financing-related dilution remains a durable risk.
Century Therapeutics News
IPSC FAQ
What was Century Therapeutics’s price range in the past 12 months?
Century Therapeutics lowest stock price was $0.43 and its highest was $3.04 in the past 12 months.
What is Century Therapeutics’s market cap?
Century Therapeutics’s market cap is $378.45M.
When is Century Therapeutics’s upcoming earnings report date?
Century Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 61 days.
How were Century Therapeutics’s earnings last quarter?
Century Therapeutics released its earnings results on Aug 12, 2026. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.11 by -$0.06.
Is Century Therapeutics overvalued?
According to Wall Street analysts Century Therapeutics’s price is currently Undervalued.
Does Century Therapeutics pay dividends?
Century Therapeutics does not currently pay dividends.
What is Century Therapeutics’s EPS estimate?
Century Therapeutics’s EPS estimate is -0.12.
How many shares outstanding does Century Therapeutics have?
Century Therapeutics has 181,075,320 shares outstanding.
What happened to Century Therapeutics’s price movement after its last earnings report?
Century Therapeutics reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.11. Following the earnings report the stock price went down -4.854%.
Which hedge fund is a major shareholder of Century Therapeutics?
Currently, no hedge funds are holding shares in IPSC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Century Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.90 (175.70% Upside)
$5.90 (175.70% Upside)
Blogger Sentiment
Bullish
IPSC Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $11.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
341.42%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.81%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Century Therapeutics
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
IPSC Stock 12 Month Forecast
Average Price Target
$5.90
▲(175.70% Upside)
Technical Analysis
Tempest Therapeutics
―
Actinium Pharmaceuticals
―
Bioxcel Therapeutics
―
Lantern Pharma
―
CalciMedica
―
Ownership Overview
3.28% Insiders
3.53% Mutual Funds
62.17% Other Institutional Investors
24.11% Public Companies and
Individual Investors